These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 18471516)

  • 1. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response.
    Asahina Y; Izumi N; Hirayama I; Tanaka T; Sato M; Yasui Y; Komatsu N; Umeda N; Hosokawa T; Ueda K; Tsuchiya K; Nakanishi H; Itakura J; Kurosaki M; Enomoto N; Tasaka M; Sakamoto N; Miyake S
    Gastroenterology; 2008 May; 134(5):1396-405. PubMed ID: 18471516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
    Asahina Y; Tsuchiya K; Muraoka M; Tanaka K; Suzuki Y; Tamaki N; Hoshioka Y; Yasui Y; Katoh T; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nitta S; Sakamoto N; Izumi N
    Hepatology; 2012 Jan; 55(1):20-9. PubMed ID: 21898478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Kitabatake S; Murakami Y
    Cytokine; 2013 Aug; 63(2):145-50. PubMed ID: 23673288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
    Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
    Moucari R; Ripault MP; Oulès V; Martinot-Peignoux M; Asselah T; Boyer N; El Ray A; Cazals-Hatem D; Vidaud D; Valla D; Bourlière M; Marcellin P
    J Hepatol; 2007 Apr; 46(4):596-604. PubMed ID: 17218037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of serum metabolites in patients with chronic hepatitis C receiving pegylated interferon plus ribavirin: a metabolomics analysis.
    Saito T; Sugimoto M; Igarashi K; Saito K; Shao L; Katsumi T; Tomita K; Sato C; Okumoto K; Nishise Y; Watanabe H; Tomita M; Ueno Y; Soga T
    Metabolism; 2013 Nov; 62(11):1577-86. PubMed ID: 23953890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
    Baker RD; Dee D; Baker SS
    J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C.
    Yang SS; Fu LS; Chang CS; Yeh HZ; Chen GH; Kao JH
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1789-93. PubMed ID: 17074015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
    Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
    J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.
    Taylor MW; Tsukahara T; Brodsky L; Schaley J; Sanda C; Stephens MJ; McClintick JN; Edenberg HJ; Li L; Tavis JE; Howell C; Belle SH
    J Virol; 2007 Apr; 81(7):3391-401. PubMed ID: 17267482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia.
    Zeuzem S; Buti M; Ferenci P; Sperl J; Horsmans Y; Cianciara J; Ibranyi E; Weiland O; Noviello S; Brass C; Albrecht J
    J Hepatol; 2006 Jan; 44(1):97-103. PubMed ID: 16290907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
    J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferons and hepatitis C virus.
    Heim MH
    Swiss Med Wkly; 2012; 142():w13586. PubMed ID: 22573217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.